Winning researchers unlocked GLP-1 drugs for obesity

Meagan Phelan

DOI: https://doi.org/10.1126/science.adq6452

IF: 56.9

2024-05-31

Science

Abstract:Award recognizes individuals whose work best underpins the Science Breakthrough of the Year

multidisciplinary sciences

What problem does this paper attempt to address?

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

Jeffrey M Friedman

DOI: https://doi.org/10.1073/pnas.2415550121

2024-09-24

Abstract:The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity. Each of the three had a distinct set of skills that made this advance possible; Habener is an endocrinologist and molecular biologist, Mojsov is a peptide chemist, and Knudsen is a pharmaceutical scientist. Their collective efforts have done what few thought possible-the development of highly effective medicines for reducing weight. Their research has also solved a mystery that began more than a century ago.
Obesity-drug pioneers win prestigious Lasker Award for medical science

Mariana Lenharo

DOI: https://doi.org/10.1038/d41586-024-03078-x

IF: 64.8

2024-09-20

Nature

Abstract:Three scientists are honoured for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way? Three scientists are honoured for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

multidisciplinary sciences
Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Dinah V Parums

DOI: https://doi.org/10.12659/MSM.946675

2024-10-01

Abstract:Rising levels of obesity in all age groups are associated with profound effects on health and economies in developed and developing countries. This year, the scientific research behind the development of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 analogs or incretin mimetics) has been recognized. On 19 September 2024, three scientists were presented with a Lasker Award for their basic clinical research on identifying and studying the roles of GLP-1. The research by Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen began three decades ago and has led to new anti-obesity drugs, which mimic GLP-1 to lower blood glucose levels and control appetite. The efficacy of GLP-1 receptor agonists in the management of obesity in adults, as well as in children and adolescents, has now been supported by several clinical trials. This editorial aims to describe the research behind developing GLP-1 receptor agonists and their potential and pitfalls in managing obesity in all age groups.
Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions

Arne Astrup

DOI: https://doi.org/10.1038/s41430-024-01460-6

2024-06-19

European Journal of Clinical Nutrition

Abstract:Scientists were chasing an incretin hormone, and when GLP-1 was finally discovered, we found that it had a pronounced satiety effect, slowed down gastric emptying, and actually reduced postprandial insulin response. These mechanisms are the basis for the highly efficacious GLP-1 analogues that today offer safe and effective treatment in millions of people living with obesity. Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.

nutrition & dietetics
The benefits of GLP-1 drugs beyond obesity

Daniel J. Drucker

DOI: https://doi.org/10.1126/science.adn4128

IF: 56.9

2024-07-19

Science

Abstract:Glucagon-like peptide–1–based medicines have weight loss–independent actions

multidisciplinary sciences
How GLP-1 went from being a hard-to-handle hormone to a blockbuster success

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00177-2

IF: 112.288

2024-11-02

Nature Reviews Drug Discovery

Abstract:Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs. Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs.

pharmacology & pharmacy,biotechnology & applied microbiology
Are GLP-1R agonists the long-sought-after panacea for obesity?

Georgina K C Dowsett,Giles S H Yeo,Georgina K.C. Dowsett,Giles S.H. Yeo

DOI: https://doi.org/10.1016/j.molmed.2023.06.008

2023-07-17

Trends in Molecular Medicine

Abstract:Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists are hugely effective in the treatment of obesity. Originally developed for type 2 diabetes (T2D), these drugs cause dramatic weight loss in people with overweight or obesity, but how do they work, and are these therapeutics the long-sought-after solution to obesity? Here we explain the mechanisms of action of GLP-1R agonists in the context of weight loss and discuss their importance as therapeutics for obesity treatment.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Brian Finan,Tao Ma,Nickki Ottaway,Timo D. Müller,Kirk M. Habegger,Kristy M. Heppner,Henriette Kirchner,Jenna Holland,Jazzminn Hembree,Christine Raver,Sarah H. Lockie,David L. Smiley,Vasily Gelfanov,Bin Yang,Susanna Hofmann,Dennis Bruemmer,Daniel J. Drucker,Paul T. Pfluger,Diego Perez-Tilve,Jaswant Gidda,Louis Vignati,Lianshan Zhang,Jonathan B. Hauptman,Michele Lau,Mathieu Brecheisen,Sabine Uhles,William Riboulet,Emmanuelle Hainaut,Elena Sebokova,Karin Conde-Knape,Anish Konkar,Richard D. DiMarchi,Matthias H. Tschöp

DOI: https://doi.org/10.1126/scitranslmed.3007218

IF: 17.1

2013-10-30

Science Translational Medicine

Abstract:Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals.

cell biology,medicine, research & experimental
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Jang Won Son,Soo Lim

DOI: https://doi.org/10.3803/enm.2024.1940

IF: 3.4

2024-04-30

Endocrinology and Metabolism

Abstract:Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein–coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1–glucagon and GIP–GLP-1–glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.

endocrinology & metabolism
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Jens Juul Holst

DOI: https://doi.org/10.1038/s42255-024-01113-9

IF: 19.865

2024-08-20

Nature Metabolism

Abstract:The introduction of the highly potent incretin receptor agonists semaglutide and tirzepatide has marked a new era in the treatment of type 2 diabetes and obesity. With normalisation of glycated haemoglobin levels and weight losses around 15–25%, therapeutic goals that were previously unrealistic are now within reach, and clinical trials have documented that these effects are associated with reduced risk of cardiovascular events and premature mortality. Here, I review this remarkable development from the earliest observations of glucose lowering and modest weight losses with native glucagon-like peptide (GLP)-1 and short acting compounds, to the recent development of highly active formulations and new molecules. I will classify these agents as GLP-1-based therapies in the understanding that these compounds or combinations may have actions on other receptors as well. The physiology of GLP-1 is discussed as well as its mechanisms of actions in obesity, in particular, the role of sensory afferents and GLP-1 receptors in the brain. I provide details regarding the development of GLP-1 receptor agonists for anti-obesity therapy and discuss the possible mechanism behind their beneficial effects on adverse cardiovascular events. Finally, I highlight new pharmacological developments, including oral agents, and discuss important questions regarding maintenance therapy.

endocrinology & metabolism
Transforming obesity: The advancement of multi-receptor drugs

Christine M. Kusminski,Diego Perez-Tilve,Timo D. Müller,Richard D. DiMarchi,Matthias H. Tschöp,Philipp E. Scherer

DOI: https://doi.org/10.1016/j.cell.2024.06.003

IF: 64.5

2024-07-26

Cell

Abstract:Recent advancements in obesity treatment, such as GLP-1-based polyagonists, offer significant weight reduction and beneficial effects on glycemia, the cardiovascular system, and adipose tissue. This review article discusses the recent advancements in multi-receptor drugs for treating obesity.

cell biology,biochemistry & molecular biology
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Robert M. Gutgesell,Rubén Nogueiras,Matthias H. Tschöp,Timo D. Müller

DOI: https://doi.org/10.1007/s13300-024-01566-x

2024-04-06

Diabetes Therapy

Abstract:The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery. However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gut–brain communication can be leveraged to achieve sustained body weight loss without adverse effects.

endocrinology & metabolism
Engineering a Pathway to Glucose-Responsive Therapeutics

Matthew J Webber,Matthew J. Webber

DOI: https://doi.org/10.2337/dbi230-029

IF: 7.7

2024-04-12

Diabetes

Abstract:In 2014, the American Diabetes Association instituted a novel funding paradigm to support diabetes research through its Pathway to Stop Diabetes® Program. Pathway took a multifaceted approach to provide key funding to diabetes researchers in advancing a broad spectrum of research programs centered on all aspects of understanding, managing, and treating diabetes. Herein the personal perspective of a 2019 Pathway Accelerator awardee is offered, describing a research program seeking to advance a materials-centered approach to engineering glucose-responsive devices and new delivery tools for better therapeutic outcomes in treating diabetes. This is offered alongside a personal reflection on five years of support from the ADA Pathway Program.

endocrinology & metabolism
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Mateus D'Ávila,Samantha Hall,Tamas L Horvath

DOI: https://doi.org/10.1210/endocr/bqae128

IF: 5.051

2024-09-26

Endocrinology

Abstract:For centuries, increasingly sophisticated methods and approaches have been brought to bear to promote weight loss. Second only to the Holy Grail of research on aging, the idea of finding a single and simple way to lose weight has long preoccupied the minds of laymen and scientists alike. The effects of obesity are far-reaching and not to be minimized; the need for more effective treatments is obvious. Is there a single silver bullet that addresses this issue without effort on the part of the individual? The answer to this question has been one of the most elusive and sought-after in modern history. Now and then, a miraculous discovery propagates the illusion that a simple solution is possible. Now there are designer drugs that seem to accomplish the task: we can lose weight without effort using mono, dual, and triple agonists of receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon. There are, however, fundamental biological principles that raise intriguing questions about these therapies beyond the currently reported side-effects. This perspective reflects upon these issues from the angle of complex goal-oriented behaviors, and systemic and cellular metabolism associated with satiety and hunger.
GLP-1 and Amylin in the Treatment of Obesity

T. Jorsal,J. Rungby,F. K. Knop,T. Vilsbøll

DOI: https://doi.org/10.1007/s11892-015-0693-3

2015-12-23

Current Diabetes Reports

Abstract:For decades, extensive research has aimed to clarify the role of pancreas and gut-derived peptide hormones in the regulation of glucose homeostasis and feeding behavior. Among these are the beta-cell hormone amylin and the intestinal L cell hormone glucagon-like peptide-1 (GLP-1). They exhibit distinct and yet several similar physiological actions including suppression of food intake, postprandial glucagon secretion, and gastric emptying—altogether lowering plasma glucose and body weight. These actions have been clinically exploited by the development of amylin and GLP-1 hormone analogs now used for treatment of diabetes and obesity. This review will outline the physiology and pharmacological potential of amylin and GLP-1, respectively, and focus on innovative peptide drug development leading to drugs acting on two or more distinct receptors, such as an amylin and GLP-1 peptide hybrid, potentially producing a more effective treatment strategy to combat the rapidly increasing global obesity.

endocrinology & metabolism
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

Daniel J Drucker

DOI: https://doi.org/10.2337/dci24-0003

2024-11-01

Diabetes Care

Abstract:The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1-based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1-based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Qiming Tan,Seun E. Akindehin,Camila E. Orsso,Richelle C. Waldner,Richard D. DiMarchi,Timo D. Müller,Andrea M. Haqq

DOI: https://doi.org/10.3389/fendo.2022.838410

IF: 6.055

2022-03-01

Frontiers in Endocrinology

Abstract:The incretin hormone glucagon-like peptide-1 (GLP-1) has received enormous attention during the past three decades as a therapeutic target for the treatment of obesity and type 2 diabetes. Continuous improvement of the pharmacokinetic profile of GLP-1R agonists, starting from native hormone with a half-life of ~2–3 min to the development of twice daily, daily and even once-weekly drugs highlight the pharmaceutical evolution of GLP-1-based medicines. In contrast to GLP-1, the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) received little attention as a pharmacological target, because of conflicting observations that argue activation or inhibition of the GIP receptor (GIPR) provides beneficial effects on systemic metabolism. Interest in GIPR agonism for the treatment of obesity and diabetes was recently propelled by the clinical success of unimolecular dual-agonists targeting the receptors for GIP and GLP-1, with reported significantly improved body weight and glucose control in patients with obesity and type II diabetes. Here we review the biology and pharmacology of GLP-1 and GIP and discuss recent advances in incretin-based pharmacotherapies.

endocrinology & metabolism
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities

Sahana Bettadapura,Katherine Dowling,Kelli Jablon,Ahmed W. Al-Humadi,Carel W. le Roux

DOI: https://doi.org/10.1038/s41366-024-01500-y

2024-03-08

International Journal of Obesity

Abstract:Glucagon-like peptide-1 (GLP-1) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the weight loss effect of these medications may be related to changes in food preferences and ingestive behaviors following the treatment. Understanding the mechanisms which impact ingestive behavior could expand opportunities to develop more refined and personalized treatment options for obesity.

endocrinology & metabolism,nutrition & dietetics
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Nasreen Alfaris,Stephanie Waldrop,Veronica Johnson,Brunna Boaventura,Karla Kendrick,Fatima Cody Stanford

DOI: https://doi.org/10.1016/j.eclinm.2024.102782

IF: 15.1

2024-08-30

EClinicalMedicine

Abstract:Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in dosing. These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects, making them an integral component of T2DM and obesity management. This review will discuss the currently approved medication for T2DM and obesity, and will also highlight the advent of novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy. Funding: National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).
Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

Aaron Novikoff,Timo D. Müller

DOI: https://doi.org/10.1152/physiol.00032.2023

IF: 11.8461

2024-02-15

Physiology

Abstract:The prevalence of obesity continues to rise in both the adolescent and adult, in parallel obesity is strongly associated with the increased incidence of type 2 diabetes (T2D), heart failure, certain types of cancer, and all-cause mortality. In relation to obesity, many pharmacological approaches of the past have tried and failed to combat the rising obesity epidemic, particularly due to insufficient efficacy or unacceptable side-effects. But while the history of anti-obesity medication is plagued by failures and disappointments, we have witnessed over the last 10 years substantial progress, particularly in regard to biochemically optimized agonists at the receptor for glucagon-like peptide-1 (GLP-1) and unimolecular co-agonists at the receptors for GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP). Although GIPR:GLP-1R co-agonists are being heralded as premier pharmacological tools for the treatment of obesity and diabetes, uncertainty remains as to why these drugs testify superiority over best-in-class GLP-1R monoagonists. Particularly with regard to GIP, there remains great uncertainty if and how GIP acts on systems metabolism and if the GIP system should be activated or inhibited to improve metabolic outcome in adjunct to GLP-1R agonism. In this review, we summarize recent advances in GLP-1- and GIP-based pharmacology, and discuss recent findings and open questions related to how the GIP system affects systemic energy and glucose metabolism.

physiology

Winning researchers unlocked GLP-1 drugs for obesity

The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity

Obesity-drug pioneers win prestigious Lasker Award for medical science

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions

The benefits of GLP-1 drugs beyond obesity

How GLP-1 went from being a hard-to-handle hormone to a blockbuster success

Are GLP-1R agonists the long-sought-after panacea for obesity?

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Transforming obesity: The advancement of multi-receptor drugs

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Engineering a Pathway to Glucose-Responsive Therapeutics

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

GLP-1 and Amylin in the Treatment of Obesity

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt